Evista


Also found in: Medical, Wikipedia.

E•vis•ta

(ɪˈvɪs tə) Trademark.
a brand of raloxifene.
References in periodicals archive ?
Reddys Laboratories Ltd announced today that it has launched Raloxifene hydrochloride tablets in 60 mg, a therapeutic equivalent generic version of Evista (raloxifene hydrochloride) tablets in the United States market, approved by the U.
The company said the US Food & Drug Administration (USFDA) approved Raloxifene hydrochloride tablets in 60 mg, is the therapeutic equivalent generic version of Evista (raloxifene hydrochloride) tablets.
When raloxifene made by Eli Lilly under the trade name of Evista entered the market in 1997, its global sales value in the first year reached up to 285 million, making it the second most successful product of Eli Lilly.
patent expirations for Cymbalta (-40% to $287 million) and Evista (-55% to $66.
In Puerto Rico, the company manufactures pharmaceutical products such as Cymbalta, Cialis, Evista, Strattera, Symbyax, Zyprexa and engages in bulk production for Humalog, Forteo and Humatrope.
Raloxifene is the generic name of Eli Lilly's Evista, which also faces generic competition in Europe.
Alternative prescription therapies for osteoporosis may include Evista (tablets with estrogen-like action), Forteo (an injectable form of synthetic parathyroid hormone), and Calcitonin (a nasal spray or injectable form of a hormone involved in calcium metabolism).
But a newer drug raloxifene, sold as Evista is safer, a private news channel reported.
a subsidiary of Ranbaxy in Romania, will market the osteoporosis medication Evista in Romania.
The United States District Court for the Southern District of Indiana upheld Eli Lilly and Company's (Indianapolis, IN) method-of-use patents on Evista (raloxifene HCl tablets).
Eli Lilly and Co has said that a federal judge issued a preliminary injunction preventing the launch of a generic version of osteoporosis drug Evista.